Barclays PLC Has $117,000 Stock Holdings in Waldencast plc (NASDAQ:WALD)

Barclays PLC grew its holdings in Waldencast plc (NASDAQ:WALD) by 301.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 32,436 shares of the company’s stock after buying an additional 24,355 shares during the quarter. Barclays PLC’s holdings in Waldencast were worth $117,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Point72 Asia Singapore Pte. Ltd. increased its stake in shares of Waldencast by 293.9% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 6,854 shares of the company’s stock valued at $25,000 after buying an additional 5,114 shares in the last quarter. Marshall Wace LLP bought a new position in Waldencast in the second quarter valued at about $37,000. Bleakley Financial Group LLC boosted its holdings in Waldencast by 75.2% in the third quarter. Bleakley Financial Group LLC now owns 26,297 shares of the company’s stock valued at $96,000 after acquiring an additional 11,288 shares during the last quarter. Catalina Capital Group LLC bought a new position in Waldencast in the third quarter valued at about $58,000. Finally, McAdam LLC bought a new position in Waldencast in the third quarter valued at about $62,000. 41.97% of the stock is currently owned by institutional investors and hedge funds.

Waldencast Trading Down 0.3 %

Shares of WALD opened at $3.15 on Thursday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.78 and a current ratio of 1.47. Waldencast plc has a 1 year low of $2.40 and a 1 year high of $11.00. The stock’s 50-day moving average price is $3.51 and its two-hundred day moving average price is $3.46.

Analyst Ratings Changes

Several research firms recently issued reports on WALD. Canaccord Genuity Group began coverage on Waldencast in a report on Friday, October 25th. They issued a “buy” rating and a $5.00 price target on the stock. Telsey Advisory Group reiterated an “outperform” rating and issued a $6.00 price target on shares of Waldencast in a report on Monday, November 18th. Canaccord Genuity Group raised their price target on Waldencast from $5.00 to $6.00 and gave the company a “buy” rating in a report on Friday, November 22nd. DA Davidson raised their price target on Waldencast from $7.25 to $7.50 and gave the company a “buy” rating in a report on Wednesday, December 4th. Finally, TD Cowen began coverage on Waldencast in a report on Monday, December 16th. They set a “hold” rating and a $4.30 target price on the stock. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Waldencast currently has an average rating of “Moderate Buy” and a consensus price target of $5.76.

Waldencast Profile

Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians.